

CLAIMS

1. Use of a PTH receptor agonist for ameliorating symptoms associated with the growth of bone metastasized cancer or bone-originated cancer in the preparation of a medicament which, when administered to an individual in an effective amount reduces bone loss, reduces bone fracturing, or reduces pain.
2. Use according to claim 1, wherein said administered effective amount reduces pain.
3. Use according to any of claims 1-2, wherein said PTH receptor agonist is PTH or an analogue thereof.
4. Use according to claim 3, wherein said PTH or an analogue thereof is PTH (1-34), preferably teriparatide acetate.
5. Use according to any of claims 1-2, wherein said PTH receptor agonist is parathyroid hormone-related protein or an analogue thereof.
6. Use according to any of claims 1-2, wherein said individual has bone metastasized cancer.
7. Use according to claim 6, wherein said bone metastasized cancer is breast cancer, prostate cancer, lung cancer, kidney cancer or thyroid cancer or myeloma.
8. Use according to any of claims 1-2, wherein said individual has bone-originated cancer.
9. Use according to any of claims 1-2, wherein said bone originated cancer is sarcoma.
10. Use according to any one of claims 1-9, wherein the effective amount of the PTH receptor agonist is from 0.1 to 1000 micrograms, preferably from 20 to 200 micrograms.